Genprex Names Seasoned IP Executive, Thomas C. Gallagher, as Senior Vice President of Intellectual Property and Licensing
September 21 2020 - 8:17AM
Business Wire
Gallagher’s appointment demonstrates the
Company’s commitment to building a world-class intellectual
property portfolio
Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a
clinical-stage gene therapy company developing potentially
life-changing technologies for patients with cancer and diabetes,
today announced it has named Thomas C. Gallagher, Esq. as the
Company’s Senior Vice President of Intellectual Property and
Licensing. Mr. Gallagher has extensive experience in the area of
biotechnology intellectual property (IP) law, business development,
and licensing transactions with industry and academic
institutions.
“Mr. Gallagher will play a critical role in advancing our
expanding intellectual property estate by spearheading IP strategy,
which is an important element of the Company’s overall success and
value creation. A seasoned biotech executive, he will provide
significant support as we execute on broadening our research and
development programs, explore opportunities for partnerships on our
existing programs, and opportunistically acquire new technologies
to further expand our pipeline,” said Rodney Varner, President and
Chief Executive Officer of Genprex.
Mr. Gallagher has more than 20 years of experience as an
intellectual property attorney. Prior to joining Genprex, he served
as Principal at the Fenagh Group, an IP and licensing consultancy
providing clients in the healthcare sector guidance on all aspects
of patent and trademark portfolio management, intellectual property
due diligence, freedom-to-operate analysis and related
transactional work. He has also served as Senior Vice President of
Intellectual Property and Licensing at Kadmon Corporation, LLC, a
biopharmaceutical company based in Manhattan. Prior to joining
Kadmon, he served as in-house IP counsel at Neostem Inc. (now
Caladrius Biosciences, Inc.), a company focused on stem cell
biology. Previously, he held several positions at ImClone Systems
Incorporated, most recently as Vice President of Intellectual
Property and Licensing. While at ImClone, he was responsible for
all aspects of intellectual property and led the IP function in
multiple due diligence undertakings by major pharmaceutical
companies, which resulted in a $2 billion strategic investment, the
highest-valued biotech deal ever at the time, and the eventual sale
of the company to Eli Lilly and Company for $6.5 billion.
Mr. Gallagher is experienced in both patent prosecution and
litigation, as well as intellectual property issues relating to
business development and licensing matters. His patent litigation
experience includes European litigation and opposition proceedings.
In addition to a law degree, Mr. Gallagher holds a Master’s degree
in molecular biology. Before becoming an attorney, Mr. Gallagher
worked as a molecular biologist in France, Spain and the United
States.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company
developing potentially life-changing technologies for patients with
cancer and diabetes. Genprex’s technologies are designed to
administer disease-fighting genes to provide new treatment options
for large patient populations with cancer and diabetes who
currently have limited treatment options. Genprex works with
world-class institutions and collaborators to develop drug
candidates to further its pipeline of gene therapies in order to
provide novel treatment approaches. The Company’s lead product
candidate, GPX-001 (quaratusugene ozeplasmid), is being evaluated
as a treatment for non-small cell lung cancer (NSCLC). GPX-001 has
a multimodal mechanism of action that has been shown to interrupt
cell signaling pathways that cause replication and proliferation of
cancer cells; re-establish pathways for apoptosis, or programmed
cell death, in cancer cells; and modulate the immune response
against cancer cells. GPX-001 has also been shown to block
mechanisms that create drug resistance. In January 2020, the U.S.
Food and Drug Administration granted Fast Track Designation for
GPX-001 for NSCLC in combination therapy with osimertinib
(AstraZeneca’s Tagrisso®) for patients with EFGR mutations whose
tumors progressed after treatment with osimertinib alone. For more
information, please visit the Company’s web site at www.genprex.com
or follow Genprex on Twitter, Facebook and LinkedIn.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the effect of Genprex’s product candidates, alone and in
combination with other therapies, on cancer and diabetes, regarding
potential, current and planned clinical trials, regarding the
Company’s future growth and financial status and regarding our
commercial partnerships and intellectual property licenses. Risks
that contribute to the uncertain nature of the forward-looking
statements include the presence and level of the effect of our
product candidates, alone and in combination with other therapies,
on cancer; the timing and success of our clinical trials and
planned clinical trials of GPX-001, alone and in combination with
targeted therapies and/or immunotherapies, and whether our other
potential product candidates, including GPX-002, our gene therapy
in diabetes, advance into clinical trials; the success of our
strategic partnerships, including those relating to manufacturing
of our product candidates; the timing and success at all of
obtaining FDA approval of GPX-001 and our other potential product
candidates including whether we receive fast track or similar
regulatory designations; costs associated with developing our
product candidates, whether we identify and succeed in acquiring
other technologies and whether patents will ever be issued under
patent applications that are the subject of our license agreements
or otherwise. These and other risks and uncertainties are described
more fully under the caption “Risk Factors” and elsewhere in our
filings and reports with the United States Securities and Exchange
Commission. All forward-looking statements contained in this press
release speak only as of the date on which they were made. We
undertake no obligation to update such statements to reflect events
that occur or circumstances that exist after the date on which they
were made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200921005165/en/
Genprex, Inc. (877) 774-GNPX (4679)
Investor Relations GNPX Investor Relations (877) 774-GNPX
(4679) ext. #2 investors@genprex.com
Media Contact Genprex Media Relations Kalyn Dabbs (877)
774-GNPX (4679) ext. #3 media@genprex.com
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Apr 2023 to Apr 2024